Key result
Review highlights statin efficacy, muscle symptom mechanisms, and critical interactions with ticagrelor.
Why the study?
This article examines the efficacy and safety of statins, reasons for failing to achieve target lipid levels, mechanisms of statin-associated muscle symptoms, and drug interactions with P2Y12 inhibitors such as ticagrelor.
This review summarizes the causes and mechanisms of statin-associated muscle symptoms, failure to achieve target lipid levels, and clinically relevant drug interactions between statins and P2Y12 inhibitors such as ticagrelor.
Answers are grounded in this paper and cite their sources.
Statin safety issues and ticagrelor interactions merit monitoring; leaves open optimal strategies for lipid targets.
This article examines the efficacy and safety of statins. It examines the main reasons for failure to achieve target lipid levels. The causes of adverse reactions to these medications, their incidence, and possible mechanisms for the development of statin-associated muscle symptoms are analyzed. The article discusses drug interactions between statins and other medications, particularly the coadministration of statins and P2Y12 platelet receptor inhibitors, primarily ticagrelor.
No takes yet. Share an insight, caveat, or question.
Belyaeva et al. (2026) conducted a review in Dyslipidemia and statin-associated muscle symptoms. Statins was evaluated. Statins are reviewed regarding their efficacy, mechanisms of statin-associated muscle symptoms, and drug interactions with P2Y12 inhibitors such as ticagrelor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: